Liver fibrosis and its response to avapritinib in 2 patients with systemic mastocytosis
Blood Adv
.
2022 Oct 25;6(20):5630-5633.
doi: 10.1182/bloodadvances.2022008038.
Authors
Karla Cavazos
1
,
Sheila Eswaran
2
,
Cathleen Maidlow
1
,
Fatma Keklik Karadag
3
,
Ramazan Idilman
4
,
Ilkay Idilman
5
,
Ira Miller
6
,
Jamile Shammo
1
,
Nancy Reau
2
,
Celalettin Ustun
1
Affiliations
1
Division of Hematology, Oncology, and Cellular Therapy, Department of Medicine, Rush University Medical Center, Chicago, IL.
2
Division of Gastroenterology, Hepatology, and Nutrition, Rush University Medical Center, Chicago, IL.
3
Division of Hematology, Department of Medicine, Ege University, Izmir, Turkey.
4
Division of Gastroenterology, Department of Medicine, Ankara University, Ankara, Turkey.
5
Department of Radiology, Hacettepe University, Ankara, Turkey.
6
Department of Pathology, Rush University Medical Center, Chicago, IL.
PMID:
35839085
PMCID:
PMC9647789
DOI:
10.1182/bloodadvances.2022008038
No abstract available
MeSH terms
Humans
Liver Cirrhosis
Mastocytosis, Systemic* / drug therapy
Mastocytosis, Systemic* / genetics
Pyrazoles / therapeutic use
Pyrroles
Substances
avapritinib
Pyrazoles
Pyrroles